Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Working Capital Changes (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Other Working Capital Changes for 8 consecutive years, with -$1.3 million as the latest value for Q1 2026.

  • Quarterly Other Working Capital Changes rose 87.26% to -$1.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$28.4 million through Feb 2026, up 23.05% year-over-year, with the annual reading at -$37.0 million for FY2025, 29.53% down from the prior year.
  • Other Working Capital Changes for Q1 2026 was -$1.3 million at Nurix Therapeutics, up from -$32.7 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $24.5 million in Q4 2023, with the low at -$32.7 million in Q4 2025.
  • Average Other Working Capital Changes over 5 years is -$2.7 million, with a median of -$1.5 million recorded in 2024.
  • The sharpest move saw Other Working Capital Changes tumbled 6520.91% in 2022, then skyrocketed 2215.31% in 2023.
  • Over 5 years, Other Working Capital Changes stood at -$1.2 million in 2022, then surged by 2215.31% to $24.5 million in 2023, then tumbled by 197.25% to -$23.8 million in 2024, then plummeted by 37.37% to -$32.7 million in 2025, then soared by 96.17% to -$1.3 million in 2026.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at -$1.3 million, -$32.7 million, and $11.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.